SUPPRESSION OF IN-VITRO TYPE-17 RESPONSES IN SPA PATIENTS USING SMALL MOLECULE ROR-gamma T INHIBITORS
Autors principals: | De Wit, J, Al-Mossawi, M, Huhn, M, Arancibia, C, Powrie, F, Bowness, P |
---|---|
Format: | Journal article |
Publicat: |
2014
|
Ítems similars
-
RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease.
per: de Wit, J, et al.
Publicat: (2015) -
Small molecule inhibitors of RORγt for Th17 regulation in inflammatory and autoimmune diseases
per: Jiuping Zeng, et al.
Publicat: (2023-06-01) -
BROMODOMAIN INHIBITORS REDUCE TH17-TYPE RESPONSES IN SPONDYLOARTHRITIS IN VITRO
per: Hammitzsch, A, et al.
Publicat: (2014) -
Small molecule allosteric inhibitors of RORγt block Th17-dependent inflammation and associated gene expression in vivo.
per: Steven A Saenz, et al.
Publicat: (2021-01-01) -
A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells
per: Amineh Ghaderi, et al.
Publicat: (2021-08-01)